INDV
NASDAQ · Pharmaceuticals
Indivior Pharmaceuticals Inc
$28.79
-0.60 (-2.04%)
Financial Highlights (FY 2026)
Revenue
1.11B
Net Income
2.81M
Gross Margin
85.3%
Profit Margin
0.3%
Rev Growth
+14.5%
D/E Ratio
5.43
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.3% | 85.3% | 64.4% | 64.4% |
| Operating Margin | 2.7% | 2.4% | 23.4% | 18.6% |
| Profit Margin | 0.3% | 0.2% | 17.8% | 21.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.11B | 968.83M | 1.33B | 1.20B |
| Gross Profit | 946.07M | 826.12M | 854.39M | 775.01M |
| Operating Income | 29.85M | 23.46M | 310.13M | 224.17M |
| Net Income | 2.81M | 2.21M | 235.99M | 261.45M |
| Gross Margin | 85.3% | 85.3% | 64.4% | 64.4% |
| Operating Margin | 2.7% | 2.4% | 23.4% | 18.6% |
| Profit Margin | 0.3% | 0.2% | 17.8% | 21.7% |
| Rev Growth | +14.5% | +14.5% | +22.2% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.69B | 1.69B | 497.34M | 438.37M |
| Total Equity | 311.62M | 311.62M | 1.81B | 1.56B |
| D/E Ratio | 5.43 | 5.43 | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 24.28M | 20.14M | 342.24M | 373.82M |
| Free Cash Flow | — | — | 277.67M | 230.73M |